NeoNeuro SAS is pleased to announce a collaboration with the Australian Imaging, Biomarker & Lifestyle Flagship Study of Ageing (AIBL) group. The collaboration is focused on exploring the potential of an innovative diagnostic platform developed by NeoNeuro called Aptamarkers, for the diagnosis of Alzheimer’s disease in blood serum. NeoNeuro, a subsidiary of the Canadian aptamer company, NeoVentures Biotechnology Inc. developed this platform within the IPEPs incubator at ICM in Paris. The platform provides deep fingerprints of pathology specific epitopes on a real time, quantitative basis. This research has potential to enable a biochemical basis to characterize the effect of Alzheimer’s […]
Dr. Gregory Penner will be presenting our opportunity at Bio-Europe 2016. Please join us on Wednesday November 9th. at 10:00 am room: Rheinsaal 2 on level 2
NeoNeuro has received a new grant from BPIfrance Financement, CMI- Amorcage 2 to continue our research towards the development of aptamers as diagnostic and therapeutic tools for Alzheimer’s disease.
NeoNeuro has been granted support from BPIfrance Financement under the PIA-1 program for the use of aptamers as a diagnostic and therapeutic tools in Alzheimer’s disease.